EGFR and non-small cell lung carcinoma: (11) found that compared to placebo, osimertinib significantly improved the disease-free survival (DFS) of patients with epidermal growth factor receptor (EGFR) mutation-positive, completely resected NSCLC (hazard ratio [HR]: 0.20, p < 0.001).